Respiratory muscle exercise with Power Breathe® and Respiron® in healthy people

Respiratory muscle training with Power Breathe® and Respiron® in healthy subjects - RMT: Respiratory muscle training

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

REBEC

Registry ID

RBR-6nrt3x

Enrollment

Unknown

Registered

2019-06-04

Start date

2018-08-10

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Strength Dynamometer

Interventions

The 30 participants will be randomized into three groups: G1 (n = 10) exercise group with respiron, G2 (n = 10) exercise group with Power Breath and G3 (n = 10) control group, will not perform any of

Device

E02.190.525.186

Eligibility

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 59 years, who present normal spirometry.

Exclusion criteria

Exclusion criteria: Individuals with cardiac disease; pulmonary; neurological or cognitive; smoking; retinal detachment; glaucoma; recent ophthalmic surgeries as well as corticosteroids; bronchodilators and ergogenic supplements; will be excluded from regular physical activity for less than three months.

Design outcomes

Primary

Measure	Time frame
It is expected to increase inspiratory muscle strength in G1 and G2, with no significant difference in the MIP delta (difference between pre and post intervention). G2 will not increase PImax, or it will increase less than 10 cmH2O. The increase in PImax will be considered significant through statistical tests (means comparison tests). In the delta (pre and post intervention difference) a value of 10 cmH2O will be considered a clinically significant minimum difference.	—

Measure

Time frame

It is expected to increase inspiratory muscle strength in G1 and G2, with no significant difference in the MIP delta (difference between pre and post intervention). G2 will not increase PImax, or it will increase less than 10 cmH2O. The increase in PImax will be considered significant through statistical tests (means comparison tests). In the delta (pre and post intervention difference) a value of 10 cmH2O will be considered a clinically significant minimum difference.

—

Secondary

Measure	Time frame
It is expected not to find significant changes spirometric data. CV will increase only in the Respiron group (G1), verified by means of statistical tests (Means comparison tests).	—

Countries

Brazil

Contacts

Public ContactELIZABETH;Elizabeth DE MORAIS;de Morais

PONTIFÍCIA UNIVERSIDADE CATÓLICA DE GOIÁS;Pontifícia Universidade Católica de Goiás

elizabeth.r.morais@hotmail.com;elizabeth.r.morais@hotmail.com62996050075;556296050075

Outcome results

None listed

Source: REBEC (via WHO ICTRP)